To further validate the IGF1R signaling in PSPC1-potentiated cell motility, we treated the PSPC1-overexpressing HCC cells with IGF1R specific inhibitor cyclolignan picropodophyllin (PPP) a potent inhibitor blocked its expression and activity without affecting other insulin family receptors [33,34]. The gene discussed is PSPC1; the disease is hepatocellular carcinoma.